SANUWAVE Health, Inc. (SNWV) Form 8-K — Aug 6, 2026
SANUWAVE Health reported Q2 2026 revenue of $9.7 million, down 3% from $10.1 million a year earlier, and swung to a net loss of $0.7 million versus net income of $0.6 million in Q2 2025. Adjusted EBITDA fell to $1.2 million from $3.2 million. The company withdrew its previously issued fiscal 2026 guidance, citing Medicare reimbursement developments, including an unfavorable CMS proposed rule for 2027 CPT 97610 reimbursement. Management plans to contest the rule during the comment period and expects the final rule in Q4 2026, with no new guidance until then.
Key figures
- Revenue
- 9739000
- Revenue Yoy
- -3%
- Total Assets
- 36605000
- Cash Position
- 9376000
- Shares Outstanding
- 8602309
- Total Debt Note
- Sum of current secured term loan $5,599K + non-current secured term loan $12,922K + secured revolver $655K, each net of debt issuance costs
- Gross Margin Pct
- 76.2%
- Six Month Revenue
- 19358000
- Adjusted Ebitda Q2
- 1189000
- Guidance Withdrawn
- Yes
- Revenue Prior Year Q2
- 10054000
- Cms Final Rule Expected
- Q4 2026
- Ultramist Systems Sold
- 82
- Six Month Adjusted Ebitda
- 2279000
- Gross Margin Pct Prior Year
- 78.1%
- Term Loan Repayment H1 2026
- 2875000
- Adjusted Ebitda Q2 Prior Year
- 3188000
- Applicator Revenue Growth Yoy
- 13%
- Operating Income Q2 Prior Year
- 1438000
- Ultramist Applicator Revenue
- 7300000
- Applicator Revenue Pct Of Total
- approximately 75%
- Ultramist Systems Sold Q1 2026
- 97
- Applicator Revenue Target Range
- 60-65%
- Ultramist Systems Sold Prior Year
- 116
Price after filing
Close on the filing date to close N calendar days later (from $5.97). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.